Vanda Pharmaceuticals shares soared nearly 20 percent on over 4.5 million shares traded Tuesday after reporting positive results from a Phase III study of tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder.
Going forward ... (see research report)
Copyright ® 2014. The Bedford Report. All Rights Reserved.